The Trump administration finalizes a Department of Labor rule requiring pharmacy benefit managers (PBMs) to disclose how they are compensated when they manage prescription drug benefits for self-funded employers. The rule is set to begin in 2027 and focuses on sharing fee and compensation information with employer clients.
Across outlets, the coverage centers on the same core change: PBMs must provide a broad set of data about payment and compensation arrangements to their employer customers. Multiple reports frame the regulation as increased transparency in how drug benefit middlemen are paid, while noting sharp disagreement among stakeholders about whether the rule improves oversight.
Outlets also describe the reactions to the policy. BioPharma Dive and Healthcare Dive both report that employers generally respond positively, while PBMs criticize the rule as government overreach. Other coverage emphasizes the finalization of the regulation and its scope for self-funded employer clients.
